coteauBeta Get App

ROIV

Roivant Sciences
$36.80
+5.38% Oct 21 close
Health CareS&P 400 Compare
1M3M6M1Y2Y
-5%+30%+65%+100%+136%Oct 2025Oct 2026Apr 2026
ROIVSPY
1W
+9.5%
1M
-5.6%
3M
+5.4%
6M
+26.2%
YTD
+69.6%
1Y
+105.9%

Live chart

Loading live chart…

What they do

Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications. The company's lead program consists of mosliciguat.

Healthcare · Biotechnology

For information only · Important disclosures

Grades vs sector

Momentum
92nd percentile in sector
A
12-1 return: +82.9%
Percentile within its GICS sector across the S&P 1500.
Growth
2nd percentile in sector
F
Revenue growth (YoY): -33.5%
Percentile within its GICS sector across the S&P 1500.
Value
Not enough data yet
–
Forward E/P: – · EBITDA/EV: –
Percentile within its GICS sector across the S&P 1500.
Profitability
19th percentile in sector
D
Profit margin: +0.0% · Return on equity: -8.5%
Percentile within its GICS sector across the S&P 1500.
Revisions
Not enough data yet
–
EPS estimate change, 30 days (current FY): –
30-day change in analysts' current-year EPS estimate; graded across covered stocks.

Our models

Held by 1 of 5 live models: New Highs Growth.

New Highs Growth
4.0% of the book
 HeldQuality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 Coteau Long Book
Not in the current book
Why it's in the New Highs Growth

Qualified on Biotech, -13% from 52-week high, biotech, price-only entry, 12-1 momentum +129%.

What would knock it out: Drops out if it falls outside the top 25 at the next rebalance (Oct 30). In the latest preview (2026-10-20) it is outside the top 25.

News

More news
Roivant Sciences stock surges on positive uveitis trial data
Investing.com · 23h ago
Roivant Sciences (ROIV) files 8-K: Reg FD disclosure
SEC 8-K · Oct 21
Roivant Sciences (ROIV) Stock Looks Fully Priced After A 393% Run
Simply Wall St. · Oct 18

Key stats

52-week range$17.87 – $41.81
Valuation and fundamentals

Valuation & fundamentals

Bottom line
No cash-flow valuation
Model read-out from the numbers below, not advice. Score -1 (DCF counts double).
▼Piotroski F-score2/9

Discounted cash flow

Trailing free cash flow is negative or missing, so a cash-flow DCF isn't meaningful by default. You can enter your own assumptions below.
Reverse DCFfor context, not a signal
Trailing free cash flow is zero or negative, so there's no growth rate to solve for. The price is betting on a turnaround to positive cash flow.
Edit assumptions · recalculates instantly
Your value per share–

Free cash flow = operating cash flow − capital spending, trailing 12 months (TTM to 2026-06-30). Growth default: average of 3-year revenue CAGR and latest revenue growth, capped at 30%. Years 6–10 fade linearly to terminal growth. Discount rate = 4.25% risk-free assumption + beta 1.00 (n/a) × 5% equity premium, kept within 7–13%. Bear: lower growth, +1 pt discount, 2% terminal. Bull: higher growth, −1 pt, 3%.

Multiples vs Health Care

P/E (trailing)
sector median 29.9×
 –
Forward P/E
sector median 17.6×
 –
EV / EBITDA
sector median 15.8×
 –
Price / sales
sector median 3.1×
 –
Price / book
sector median 3.5×
 –
FCF yield
sector median 4.1%
 –

Quality & financial health

Gross margin
–
Operating margin
-7914.8%
FCF margin
-10901.0%
Net margin
-3535.0%
Return on equity
-6.3%
Return on invested capital
-63.1%
Net debt / EBITDA
–
Current ratio
16.7×
Interest cover
-15.2×
Cash conversion (OCF/NI)
–
Piotroski F-score 2/9 · last two fiscal years
✗ Positive net income✗ Positive operating cash flow✗ Return on assets improved✗ Cash flow above net income✓ Long-term debt / assets fell✗ Current ratio improved✓ No share dilution✗ Gross margin improved✗ Asset turnover improved

Analysts

No analyst targets available.

Annual history

FYRevenueNet incomeFree cash flow
2026$8.3M$-299.8M$-758.6M
2025$29.1M$-172.0M$-844.0M
2024$32.7M$4.3B$-766.6M
2023$31.5M$-1.0B$-856.1M
2022$55.3M$-845.3M$-695.2M
2021$23.8M$-809.2M$-557.9M

From the company's 10-K filings via SEC XBRL. 3-year revenue CAGR -36.0%.

Earnings

Next report: 2026-11-09 · before open · EPS est -0.30
24-1125-0225-0525-0825-1126-0226-0526-08-0.360.00
EstimateActual (beat)Actual (miss)
ReportEPS estActualSurprise
2026-08-06-0.36-0.34+4.9%
2026-05-20-0.35-0.32+9.3%
2026-02-06-0.31-0.24+23.0%
2025-11-10-0.30-0.28+9.3%
2025-08-11-0.23-0.25-8.7%
2025-05-29-0.16-0.22-33.6%
2025-02-10-0.24-0.20+17.2%
2024-11-12-0.24-0.30-23.8%
Insider trades
Epperly Melissa B,
Director · 2026-10-01
Sell
$32.9K
Epperly Melissa B,
Director · 2026-10-01
Sell
$607.9K
Venker Eric
President & Immunovant CEO · 2026-09-30
Sell
$7.3M
Fitzgerald Meghan
Director · 2026-09-15
Sell
$16.2K
Fitzgerald Meghan
Director · 2026-09-15
Sell
$187.0K
Epperly Melissa B,
Director · 2026-09-15
Sell
$24.2K
Epperly Melissa B,
Director · 2026-09-15
Sell
$172.0K
Fitzgerald Meghan
Director · 2026-09-08
Sell
$798.0K
Venker Eric
President & Immunovant CEO · 2026-08-28
Sell
$1.2M
Venker Eric
President & Immunovant CEO · 2026-08-28
Sell
$5.9M
Sukhatme Mayukh
Director, President & CIO · 2026-08-21
Sell
$5.3M
Sukhatme Mayukh
Director, President & CIO · 2026-08-20
Sell
$653.5K

Stats refreshed 2026-10-21 17:58:31 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Free. Not investment advice. Unsubscribe anytime.

coteau

Independent research · Not investment advice · Important disclosures · Contact desk@coteau.app

Coteau Systematic Strategies publishes stock research and model portfolios. Results are hypothetical unless marked Live. Data: Yahoo Finance (15-min delayed), SEC EDGAR and the House Clerk.

How it worksDisclaimerTermsPrivacyData statusSend feedback
Beta 0.9 · Oct 21, 2026